Canada approves Wegovy to reduce the risk of non-fatal heart attack

The Canadian Food Inspection Agency has approved Novo Nordisk’s weight loss drug Wegovy to reduce the risk of non-fatal heart attack in adults with established cardiovascular disease. This appears from a press release.

“This is the first approved treatment in the country that supports both chronic weight control and reduces the risk of non-fatal heart attack,” writes Novo Nordisk.

Almost one in three adults in Canada is obese, which is a risk factor for heart disease.